智通财经APP讯，美诺华(603538.SH)发布公告，近日，公司全资子公司宣城美诺华药业有限公司(简称“宣城美诺华”)收到国家药品监督管理局(核准签发的沙库巴曲缬沙坦钠原料药《化学原料药上市申请批准通知书》，该药品适应症：用于治疗原发性高血压。
宣城美诺华的沙库巴曲缬沙坦钠原料药通过CDE技术审评，证明该原料药已符合国家相关药品审评技术标准，可销售至国内市场，将进一步丰富子公司的产品线，有助于拓展公司业务领域，有利于进一步扩展公司原料药制剂一体化生产范围，增强公司一体化生产的优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.